Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

This trial is testing a new experimental vaccine called VBI-1901 for patients with a type of aggressive brain cancer called glioblastoma (GBM) that has come back after previous treatment, to find the safest and most effective dose and see if it can help slow the cancer's growth. **You may be eligible if...** - You are between 18 and 70 years old - Your brain cancer has been confirmed as grade IV glioblastoma (GBM) by tissue testing - Your tumor has grown back or progressed after receiving initial treatment, which must have included surgery and radiation (with or without chemotherapy) - An MRI of your brain has been done within 30 days before starting the study - Your overall health and organ function meet the required levels **You may NOT be eligible if...** - You have not previously received standard treatment (surgery plus radiation) - Your organ function or blood counts do not meet the required levels - You have other significant health conditions that make participation unsafe Talk to your doctor to see if this trial is right for you.